The Treatment of Glabellar Frown Lines

Completed · Phase 4

Conditions studied: Glabellar Frown Lines

In brief

The purpose of this study is to show that two FDA-approved botulinum toxin drugs called Xeomin® and Botox® can reduce the severity of vertical lines (wrinkles) that appear between the eyebrows (glabellar frown lines).

Key facts

Study ID
NCT02096081
Run by
Merz North America, Inc.
People needed
250
Starts
2014-02-01
Expected to finish
2014-11-01
Last updated by the study team
2017-10-19

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.